Catalyst

Slingshot members are tracking this event:

Alexion (ALXN) Presents Data from Phase 1/2 Dose-Escalation Study of ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ALXN

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2, Dose-escalation Study, Alxn1210, Paroxysmal Nocturnal Hemoglobinuria, Pnh